 Pliant Therapeutics

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.

Belite Bio Inc

CinCor Pharma

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

3 Soaring Biotech Stocks That Could Climb Much Higher

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will present a corporate overview at the Pulmonary/Lung Disease Mini-Symposium, a part of RBC's Biotech Expert Insights Series.

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. Katharine Knobil to its Board of Directors, effective immediately.

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.

Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?

Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?

Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%

Recent independent Data Safety Monitoring Board (DSMB) review recommended  the INTEGRIS-IPF Phase 2a trial continue without modification

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

PLRX went up 200% on strong phase 2a data in IPF. Even a subsequent large dilution was unable to dampen enthusiasm.

Pliant Therapeutics: Wait For A Better Price To Get In

The mean of analysts' price targets for Pliant Therapeutics, Inc. (PLRX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%

Absci Corp

Axcella Health Inc

DiCE Molecules Holding LLC

Freeline Therapeutics Holdings

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Adicet Bio, Inc.

IVERIC bio Inc

Chinook Therapeutics

Kura Oncology

Rocket Pharma

Caribou Biosciences

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

7 Cheap Biotech Stocks to Buy Now

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BTIG Biotechnology Conference 2022.

Pliant Therapeutics to Participate in BTIG Biotechnology Conference

Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?

The consensus price target hints at a 142.4% upside potential for Pliant Therapeutics, Inc. (PLRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 142%

OrthoPediatrics

Novavax

Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.

2022 Roundtable: Our Favorite Picks Right Now

SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral, dual-selective αvß6 / αvß1 integrin inhibitor, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing cholangitis (PSC). PLN-74809, the Company's lead drug candidate, is currently being tested as part of the INTEGRIS-PSC Phase 2a clinical trial (NCT04480840). Pliant anticipates topline data from this randomized, double-blind, placebo-controlled trial in patients with PSC, in the first half of 2023.

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

Wall Street thinks this red-hot biotech stock has a lot more room to run.

Could Pliant Therapeutics Stock Double Your Money?

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering of 10,810,811 shares of its common stock at a price to the public of $18.50 per share. The aggregate gross proceeds from the offering are expected to be approximately $200.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Pliant. In addition, Pliant granted the underwriters a 30-day option to purchase up to an additional 1,621,621 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Pliant. The offering is expected to close on or about July 15, 2022, subject to the satisfaction of customary closing conditions.

Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering

Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.

Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study

Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% Monday on the company's treatment for Idiopathic Pulmonary Fibrosis, which was.

What's Going On With Pliant Therapeutics Stock?

Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?

Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering. Pliant Therapeutics shares soared by nearly 160% during Monday's regular trading session on the company's treatment for.

News for Pliant Therapeutics Stock (PLRX)